ASCENDIS PHARMA BONE DISEASES AS has a total of 49 patent applications. It decreased the IP activity by 96.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, Australia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and biotechnology are DYNOGEN PHARMACEUTICALS INC, CONARIS RES INSTITUTE AG and NANOMERICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | Australia | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 6 | |
#4 | Canada | 5 | |
#5 | EPO (European Patent Office) | 5 | |
#6 | Brazil | 4 | |
#7 | China | 4 | |
#8 | Singapore | 4 | |
#9 | Mexico | 3 | |
#10 | South Africa | 3 | |
#11 | Israel | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Sprogøe Kennett | 30 |
#2 | Karpf David Brian | 28 |
#3 | Holten-Andersen Lars | 23 |
#4 | Cleemann Felix | 12 |
#5 | Maitro Guillaume | 11 |
#6 | Zettler Joachim | 11 |
#7 | Krusch Mathias | 11 |
#8 | Wegge Thomas | 11 |
#9 | Sprogoe Kennett | 9 |
#10 | Kennett Sprogøe | 7 |
Publication | Filing date | Title |
---|---|---|
WO2020165087A1 | Liquid pharmaceutical formulations of pth conjugates | |
CA3099620A1 | Starting dose of pth conjugates | |
BR112019005793A2 | pth compounds with low peak-to-valley ratios | |
AU2017336250A1 | Incremental dose finding in controlled-release PTH compounds | |
MX2019003181A | Dosage regimen for a controlled-release pth compound. | |
EP3423103A1 | Pth prodrugs |